APC In the News
Tirzepatide fallout in The Hill
The Hill writes one of the first stories on the fallout from the FDA's tirzepatide decision.
October 11, 2024
Echoing our position
Specialty Pharmacy Continuum has a great piece on the importance of a longer "tail" for 503As.
October 10, 2024
Wired story isn’t perfect, but…
This time Wired missed the mark on pharmacy compounding, but it at least quoted Scott and focused on the important issues.
October 10, 2024
Wired focuses on GLP-1 patient fallout
Wired looks at how some patients are being hit hard by tirzepatide coming off shortage.
October 9, 2024
Quartz mentions APC
Not a big deal, but it shows we're getting media coverage across the spectrum.
October 9, 2024
San Diego news radio focuses on GLP-1 price
It could have chosen any angle, and it went with the high price of commercial versions. 👍🏻
October 9, 2024
CNN gets it spot on
The article, which of course quotes APC, focuses on the impact on patients of tirzepatide coming out of shortage.
October 9, 2024
Medscape focuses on compounders
Medscape is the latest news outlet to cover tirzepatide, and it focuses on APC's perspective.
October 7, 2024
Commenting on the tirzepatide announcement
Since the FDA announced that tirzepatide is (for now) out of shortage, APC's Scott Brunner has been all over the news offering our perspective.
October 4, 2024
Talking about those legal threats
Baseless but time-consuming lawsuit threats make compounders shy.
September 27, 2024
APC does its best in a Hill article
The piece spends a lot of time considering misconceptions about compounded GLP-1s, but it least it included a little straight info from Scott.
September 27, 2024
Weighing in on Lilly’s tirzepatide vials
Scott tells Medscape that actually helping patients with vial-based tirzepatide is a welcome change for Lilly.
September 27, 2024
Shortage compounding is not a loophole, Scott explains to Axios
"It is absolutely intentional policy on the part of FDA."
September 27, 2024
Scott predicts ongoing off-and-on shortages
Don't expect brand-name GLP1s to be available long-term, he says
September 25, 2024
Tenille talks about the cost of firefighters’ lives
The California Board of Pharmacy looked to ban glutathione, but the pushback was hard.
September 24, 2024